Peter MacCallum Cancer Centre

Contact Info:

Kaylene Simpson

https://www.petermac.org/research/research-technologies/victorian-centre-functional-genomics-vcfg

Grants and Identifiers:

RRID: RRID:SCR_025582

Instrumentation:

Services Provided:

Relevant Publications:

1.) Lai J, Chan CW, Armitage JD, Audsley KM, Huang YK, Derrick EB, Carstensen LS, Scheffler CM, Jones ME, Sek K, Principe N, Kim JS, House IG, Chen AXY, Yap KM, Middelburg J, Munoz I, Nguyen D, Tong J, Hoang TX, Todd KL, Evrard M, Chee J, Mackay LK, Forrest ARR, Parish IA, Bosco A, Waithman J, Beavis PA, Darcy PK (2026 Mar). Flt3L-mediated tumor cDC1 expansion enhances immunotherapy by priming stem-like CD8(+) T cells in lymph nodes. Nature immunology, 27(3), 530-542. . PMCID: 12956571.

2.) de Menezes MN, Chen AXY, Kulkarni N, Sampurno S, Saw NYL, Yap KM, Pérez-Núñez I, Roth S, Deguit CDT, Haugen B, Ramsbottom KM, Munoz I, Beavis PA, Parish IA (2026 Feb 17). High efficiency CRISPR knock-in demonstrates that TCF1 is insufficient to reverse T cell exhaustion. Nature communications, 17(1), . . PMCID: 13022480.

3.) Zhang X, Xu R, Zorin D, Pappas EG, Tang J, Bai Y, Qin VM, von Scheidt B, Huang R, Kulakowska W, Darido C, Darcy PK, Kershaw MH, Slaney CY (2025 Aug 21). Optimised modular anti‐FLAG CAR T cells for solid tumor therapy Clinical & Translational Immunology, 14(8), e70046. . PMCID: 12370372.

4.) Chen AXY, Yap KM, Kim JS, Sek K, Huang YK, Dunbar PA, Wiebking V, Armitage JD, Munoz I, Todd KL, Derrick EB, Nguyen D, Tong J, Chan CW, Hoang TX, Audsley KM, van Elsas MJ, Middelburg J, Lee JN, de Menezes MN, Cole TJ, Li J, Scheffler C, Scott AM, Mackay LK, Waithman J, Oliaro J, Harrison SJ, Parish IA, Lai J, Porteus MH, House IG, Darcy PK, Beavis PA (2025 Aug). Rewiring endogenous genes in CAR T cells for tumour-restricted payload delivery. Nature, 644(8075), 241-251. . PMID: 40604285.

5.) Buco PA, Tandazo-Castillo W, Chalk AM, Pilcher C, Holien JK, Heierhorst J, Tan TY, Koren A, Smeets MF, Walkley CR (2025 Jul 21). Minute amounts of helicase-deficient truncated RECQL4 are sufficient for DNA replication bioRxiv, (), 2025.07.21.666025. . PMCID: 12330659.

6.) Pishas KI, Cowley KJ, Llaurado-Fernandez M, Kim H, Luu J, Vary R, Bowden NA, Campbell IG, Carey MS, Simpson KJ, Cheasley D (2024 Sep 19). High-throughput drug screening identifies novel therapeutics for Low Grade Serous Ovarian Carcinoma Scientific Data, 11(), 1024. . PMCID: 11413243.

Description:

Core to perform novel discovery-based high throughput compound, CRISPR and RNAi screens at any scale in both 2D and 3D formats, using liquid handling instruments, automated high content imaging microscopes, live imaging systems and large reagent libraries.